Current AAV retinal gene therapy trials and therapeutic protocols, in the case of voretigene neparvovec for RPE65-associated Leber congenital amaurosis, generally include a perioperative period of systemic immunosuppression with prednisolone to reduce the risk of retinal inflammation [11,14,17]. The gene discussed is RPE65; the disease is Leber congenital amaurosis.